Technologies

Aliophen-XP is a highly concentrated polyphenolic composition derived from Aliophen®, a patented formulation based on malt and hops (Patent No. 102017000096298). Developed to enhance the original formulation, Aliophen-XP is produced through a specialized process that removes components potentially interfering with the biological activity of the bioactive compounds naturally extracted from malt and hops.

This innovative technology involves the use of a high-affinity, highly specific antibody that targets extracellular domains of connexin hemichannels (Cx26, Cx30, and Cx32). The antibody has been designed to reduce or inhibit the growth of brain tumors, particularly glioblastoma (GBM), and to alleviate the associated epilepsy. By blocking connexin hemichannels, the antibody interferes with pathological ATP release and other signaling mechanisms that contribute to tumor progression and neural hyperexcitability.

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

The portable device is intended to assess exposure to electromagnetic fields produced by an MRI equipment. The device (dosimeter) allows to improve the analysis and study of the problems related to the exposure of the operators, starting from the technical-scientific aspects related to the exposure, also allowing to create a manual of best practices as well as to improve the professional training of operators.

At IFN-CNR, in collaboration with Politecnico di Milano-Department of Physics, we have developed Raman microscopy approaches compatible with the study and characterization of biological and industrial samples. In detail, our facility houses a self-built spontaneous confocal Raman microscope with the following characteristics: two excitation lasers (660nm and 785nm), inverted microscope (Olympus IX-73) and Princeton spectrometer / CCD.

Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.

The invention consists of a method and apparatus for the delivery at low pressure (equal to or less than 10^-7 Torr) of monoatomic fluorine for reaction with surfaces in an ultra-clean environment. Thanks to the low pressure values involved in the proposed method, the risks associated with the use of fluorine are reduced to a minimum.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

The metasurface optomechanical modulator is a device designed to modulate the amplitude, phase and polarization of a beam of electromagnetic radiation, independently, or simultaneously, according to prescribed paths in the parameter space (for example, as regards polarization, paths on the Poincaré sphere). The concept of our device can be applied to the entire spectrum of electromagnetic waves: from radio frequency, to microwaves (GHz), to millimeter waves (THz), to far and near infrared radiation, and to visible light.

Our proposal focuses on innovative formulations containing metallic complexes and plant extracts for diabetes treatment. The formulations were tested in vitro on human adipocyte cell models, showing a strong hypoglycemic effect due to the synergistic action of the two components. The plant extracts, derived from waste biomass of the agri-food industry, possess high antioxidant activity and interesting nutraceutical properties, due to their composition rich in polyphenols.

Filamentous bacteriophages for size, in vivo biodistribution and easiness of engineering, are considered as natural nanoparticles. The developed technology allows the construction of bio-nanoparticles based on filamentous bacteriophages delivering proteic antigens and immunomodulating lipids. Thanks to the high content of hydrophobic residues, phage capsid proteins have high binding affinity to lipids, allowing the conjugation of immunostimulating lipids.

Currently, liposomes (artificially synthesised vesicles) are widely used as carriers for a variety of molecules in the cosmetic and pharmaceutical industries. In the clinical applications, for instance, they are employed to encapsulate a range of substances, such as antibiotics, proteins, genetic material, vitamins and anti-cancer drugs.